March 31, 1993 |
Ever so quietly, McNeil Pharmaceutical this year is eliminating 350 jobs at its headquarters in Spring House, Montgomery County, and moving many of them to Raritan, N.J. There, the Johnson & Johnson subsidiary will consolidate its business operations with Ortho Pharmaceutical, the Johnson & Johnson subsidiary that makes birth control pills and other drugs, said Nancy Collins, a McNeil spokeswoman. The new firm will be called Ortho-McNeil Pharmaceutical. To be transferred to New Jersey or cut will be about 70 percent of the Spring House workforce.
July 13, 1993 |
Thomas H. Odiorne, 52, a New Hope resident who was a top executive at Johnson & Johnson before leaving to help lead a fledgling biotech company, died Saturday at Doylestown Hospital. Mr. Odiorne started in 1969 as a sales representative at McNeil Pharmaceuticals, a Johnson & Johnson subsidiary in Spring House, Montgomery County, and worked his way up to the top. He was McNeil's president from 1985 to July 1989. In 1989, he went to Johnson & Johnson corporate headquarters in New Brunswick, N.J., to become president of the International Cilag-Ortho-McNeil group.
December 7, 1987 |
Johnson & Johnson will market and distribute three imaging agents being developed by Centocor Inc., the biotechnology firm in Malvern, under an agreement between the companies. The arrangement provides Centocor with a new source of income and badly needed marketing muscle. Johnson & Johnson, the health-care company based in New Brunswick, N.J., already has made an initial payment to Centocor for marketing rights to the products in the United States and several small foreign countries and will make additional payments as bench marks in the development process are achieved.
November 12, 2005 |
William H. Ashton, 87, of Huntingdon Valley, a scientist who patented products for the operating room, the bathroom and babies' bottoms, died of heart failure last Saturday at home. For more than 57 years, Mr. Ashton was associated with Johnson & Johnson as a research scientist and, after retiring in 1983, as a consultant. In 1949 he developed dental floss and dental tape for Johnson & Johnson and 30 years later patented flavored floss and tape. In the 1950s he invented resorbable sutures and later developed resorbable gauze for liver surgery.
February 15, 2013 |
BOSTON - Health care company Johnson & Johnson has been told to pay a teenager and her parents $63 million after she suffered a life-threatening drug reaction and lost most of her skin when she took a children's pain reliever nearly a decade ago. Johnson & Johnson and its Fort Washington-based McNeil-PPC Inc. subsidiary should pay Samantha Reckis and her parents a total of $109 million, including interest, a Plymouth Superior Court jury decided on...
July 25, 2010 |
A report on New Jersey gaming that reimagines Atlantic City doesn't look to Las Vegas or New York for inspiration. It looks to one of its own: New Brunswick. The authors of the report say the 35-year transformation of the small central New Jersey city, the home of Rutgers University, offers a model for turning around the struggling Shore resort. In the mid-1970s, pharmaceutical giant Johnson & Johnson created a process for redevelopment through public-private partnerships - most significantly, through a tax-exempt development company specifically for New Brunswick.
January 17, 2003 |
Johnson & Johnson said yesterday that it would acquire 3-Dimensional Pharmaceuticals Inc., of Yardley, in a cash deal valued at $88 million. The pharmaceutical and health-care products giant will pay $5.74 for each 3-Dimensional share, which closed at $5.64 yesterday on the Nasdaq stock market. The announcement sent the small company's shares soaring $2.61, or 86.1 percent, at yesterday's close. 3-Dimensional Pharmaceuticals has drugs in early-stage research for treating cardiovascular disorders, oncology and inflammation.
October 10, 1989 |
ICI said yesterday that it would sell its U.S. over-the-counter drug business to a joint venture of Merck & Co. and Johnson & Johnson for more than $450 million. The deal will contribute about $125 million in annual sales to the seven- month-old Johnson & Johnson-Merck Consumer Pharmaceuticals Co., which has yet to market any of its own products. The bulk of the revenue will be derived from the Mylanta line of antacid products and the Mylicon line of anti-gas products. In return, ICI will receive a cash payment and unspecified obligations, plus the U.S. rights to Elavil, a Merck antidepressant launched in the early 1960s.
April 19, 2011 |
The existence of talks aimed at a possible merger of Johnson & Johnson and Synthes was confirmed Monday by Synthes, which has major operations in Chester County. Synthes is a global manufacturer of medical devices with headquarters in Switzerland and West Chester and four facilities in West Chester and one in Paoli. The company is one of the dominant players in the field of repairing bones, especially in the spine and those broken by trauma. That means plates and screws, compounds, and medical power tools.